drugset

drugset / Trial / NCT06897527

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

NCT06897527 ↗

Phase 4 Not yet recruiting 100 enrolled GlaxoSmithKline

NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.

Timeline

Start: 2025-07-15
Primary completion: 2027-01-13
Completion: 2027-01-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dostarlimab	Monoclonal antibody	—	—

Indications